Home NDC 0078-1175 VIJOICE
Product NDC 0078-1175
11-digit product format 000781175
Labeler code 0078
Product ID 0078-1175_1972e01a-52a6-4de1-8a03-759cfcc4ccf3
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name alpelisib
Dosage form GRANULE
Route ORAL
Labeler Novartis Pharmaceuticals Corporation
Application NDA218466
Marketing category NDA
Marketing start 2024-04-24
Substance ALPELISIB
Active strength 50 mg/1
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N218466-001 VIJOICE ALPELISIB 50MG/PACKET GRANULE / ORAL RLD, RS 2024-04-24
Orange Book patents# Current patent rows page 1 of 1 · 4 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 N218466-001 11433059 2037-02-17 U-4359 2025-12-22 N218466-001 12427141 2037-02-17 U-4288 2025-10-20
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N218466-001 VIJOICE 50MG/PACKET GRANULE / ORAL RLD, RS 2024-04-24 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N218466-001 VIJOICE 50MG/PACKET GRANULE / ORAL RLD, RS 2024-04-24 c2088c7a36db…2026-09-14 22:38:34 2026-08 N218466-001 VIJOICE 50MG/PACKET GRANULE / ORAL RLD, RS 2024-04-24 84e616aacf4f…2026-08-18 06:07:40 2026-07 N218466-001 VIJOICE 50MG/PACKET GRANULE / ORAL RLD, RS 2024-04-24 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N218466-001 VIJOICE 50MG/PACKET GRANULES / ORAL RLD, RS 2024-04-24 8072bd15b7f6…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218466-001 VIJOICE 50MG/PACKET GRANULE / ORAL RLD, RS 2024-04-24 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 2 · 49 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218466-001 11433059 2037-02-17 U-4359 2025-12-22 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218466-001 12427141 2037-02-17 U-4288 2025-10-20 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218466-001 11433059 2037-02-17 U-4359 2025-12-22 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218466-001 12427141 2037-02-17 U-4288 2025-10-20 c2088c7a36db…2026-09-14 22:38:34 2026-08 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218466-001 11433059 2037-02-17 U-4359 2025-12-22 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218466-001 12427141 2037-02-17 U-4288 2025-10-20 84e616aacf4f…2026-08-18 06:07:40 2026-07 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218466-001 11433059 2037-02-17 U-4359 2025-12-22 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218466-001 12427141 2037-02-17 U-4288 2025-10-20 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218466-001 11433059 2037-02-17 U-4359 2025-12-22 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218466-001 12427141 2037-02-17 U-4288 2025-10-20 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218466-001 12427141 2037-02-17 U-4288 2025-10-20 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N218466-001 8227462 2033-04-29 Drug substance, Drug product 2024-05-15 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N218466-001 8476268 2029-09-10 Drug substance, Drug product 2024-05-15 79d66fd596c7…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base VIJOICE
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength ALPELISIB 50 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 08W5N2C97Q Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 16 matching rows.
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0078-1175-19 VIJOICE 1 in 1 PACKET GRANULE 1 10 0078-1175-51 VIJOICE 28 in 1 CARTON GRANULE 28 10
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0078-1175 VIJOICE (ALPELISIB) TABLET VIJOICE (ALPELISIB) KIT VIJOICE (ALPELISIB) GRANULE [NOVARTIS PHARMACEUTICALS CORPORATION] 7 Current NDC, 2 package rows 20240724_638069a4-aee0-46c9-9e21-54ad449c163c.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join VIJOICE ALPELISIB Novartis Pharmaceuticals Corporation 638069a4-aee0-46c9-9e21-54ad449c163c 2026-10-27 Warnings, Adverse reactions Exact identifier application applno (NDA): 218466 application number: NDA218466 ndc (product): 0078-1175
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 0078-1175-19 00078117519 1 in 1 PACKET Historical 0078-1175-51 00078117551 28 PACKET in 1 CARTON (0078-1175-51) / 1 GRANULE in 1 PACKET (0078-1175-19) 28 packet 2024-04-24 No No Current